Theseus Pharma terminates CEO and CMO; appoints CFO Dahms as President

Theseus Pharmaceuticals, Inc.

CEO Timothy Clackson and CMO David Kerstein terminated without cause effective Dec 7, 2023 as part of workforce reduction.
Clackson receives $0.9M severance plus 18-month equity vesting; Kerstein receives $0.6M plus 12-month equity vesting.
CFO Bradford Dahms appointed President and director; salary increased to $500K; eligible for retention bonus of 1.5x salary.
Dahms retention bonus paid in two installments; requires employment through earlier of strategic transaction or Feb 28, 2024.
Both departing executives entered consulting agreements through Mar 31, 2024.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Timothy P. Clackson

President and Chief Executive Officer

Theseus Pharmaceuticals, Inc.

Effective: 2023-12-07
Filed: December 4, 2023, 6:59 PM ET

the Company terminated the employment of Timothy P. Clackson, Ph.D. as President and Chief Executive Officer of the Company, effective as of December 7, 2023

Departed

David Kerstein

Chief Medical Officer

Theseus Pharmaceuticals, Inc.

Effective: 2023-12-07
Filed: December 4, 2023, 6:59 PM ET

the Company also terminated the employment of David Kerstein, M.D. as the Chief Medical Officer of the Company, effective as of the Separation Date

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Timothy P. Clackson was terminated as President and Chief Executive Officer at Theseus Pharmaceuticals, Inc..

Action: terminated
Role: President and Chief Executive Officer

Exact text from the filing

the Company terminated the employment of Timothy P. Clackson, Ph.D. as President and Chief Executive Officer of the Company, effective as of December 7, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David Kerstein was terminated as Chief Medical Officer at Theseus Pharmaceuticals, Inc..

Action: terminated
Role: Chief Medical Officer

Exact text from the filing

the Company also terminated the employment of David Kerstein, M.D. as the Chief Medical Officer of the Company, effective as of the Separation Date

View on SEC.gov

Source: SEC EDGAR

accession 0001104659-23-123002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.